U.S. Markets closed
  • S&P 500

    3,870.29
    -31.53 (-0.81%)
     
  • Dow 30

    31,391.52
    -143.99 (-0.46%)
     
  • Nasdaq

    13,358.79
    -230.04 (-1.69%)
     
  • Russell 2000

    2,231.51
    -43.81 (-1.93%)
     
  • Crude Oil

    59.42
    -0.33 (-0.55%)
     
  • Gold

    1,735.90
    +2.30 (+0.13%)
     
  • Silver

    26.85
    -0.03 (-0.11%)
     
  • EUR/USD

    1.2090
    +0.0003 (+0.0242%)
     
  • 10-Yr Bond

    1.4150
    -0.0310 (-2.14%)
     
  • Vix

    24.10
    +0.75 (+3.21%)
     
  • GBP/USD

    1.3957
    +0.0001 (+0.0042%)
     
  • USD/JPY

    106.7340
    +0.0240 (+0.0225%)
     
  • BTC-USD

    48,694.82
    -1,013.58 (-2.04%)
     
  • CMC Crypto 200

    973.93
    -12.72 (-1.29%)
     
  • FTSE 100

    6,613.75
    +25.22 (+0.38%)
     
  • Nikkei 225

    29,527.75
    +119.58 (+0.41%)
     

Coherus BioSciences to Report Third Quarter Financial Results on November 5th

  • Oops!
    Something went wrong.
    Please try again later.
Coherus BioSciences, Inc.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

REDWOOD CITY, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2020 financial results will be released after market close on Thursday, November 5, 2020. Starting at 4:30 p.m. EST, Coherus’ management team will host a conference call to discuss financial results and provide a general business update.

After releasing third quarter financial results, the Company will post them on the Coherus website at https://investors.coherus.com.

Conference Call Information

When: Thursday, November 5, 2020 starting at 4:30 p.m. EST

Webcast: https://investors.coherus.com

Dial-in: 844-452-6826 (Toll-Free U.S. and Canada) or 765-507-2587 (International)
Please dial-in 15 minutes early to ensure a timely connection to the call.

Conference ID: 7079429

About Coherus BioSciences, Inc.

Coherus is a leading biosimilar company that develops and commercializes its own high-quality therapeutics as well as those of others seeking capable access to the United States market. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales and marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus commercializes UDENYCA® (pegfilgrastim-cbqv) in the United States and is advancing additional product candidates including CHS-1420, a Humira® (adalimumab) biosimilar, Bioeq’s Lucentis® (ranibizumab) biosimilar, Innovent’s Avastin® (bevacizumab) biosimilar towards commercialization, as well as CHS-2020, an Eylea® (aflibercept) biosimilar. For additional information, please visit www.coherus.com.

Contact

David S. Arrington
Investor Relations & Corporate Affairs
Coherus BioSciences, Inc.
darrington@coherus.com
+1 (650) 395-0196